Document:

emergentbiosolutionsaa7f

Certain identified information has been excluded from the exhibit because it is both (i) not  material and (ii) is the type of information that the registrant treats as private or confidential.  Double asterisks denote omissions.  Exhibit 10.14      CHANGE ORDER NO. 5 TO WORK ORDER #5997-01 – [**] STUDY  This Change Order No. 5 entitled — [**] STUDY (“Change Order No. 5”) effective as of  September 16, 2020 (“Change Order No. 5 Effective Date”) to Work Order #5997-01 by and  between AstraZeneca Pharmaceuticals LP (“Astrazeneca”) and Emergent Manufacturing  Operations Baltimore, LLC (“Service Provider”) hereby adds to the scope of Services set forth  in Work Order #5997-01 entered into by the Parties pursuant to the Master Services Agreement  dated July 24, 2020 (the “Master Services Agreement”).  Capitalized terms used in this Change  Order that are not otherwise defined herein have the meanings given to them in the Master Services  Agreement.  In consideration of the mutual promises contained therein and herein and for other good  and valuable consideration the receipt and adequacy of which each of the Parties does hereby  acknowledge, the Parties hereby agree as follows:  1. Purpose and Description of Change.  The purpose of this Change Order No. 5 is to further  add to the Services set forth in Work Order #5997-01.  In addition to the Services set  forth in Work Order #5997-01(including without limitation, within prior Change Orders),  Service Provider will render to Astrazeneca the following Services:  This [**] study will be performed by the Service Provider.  The intent of this study will be to  evaluate the [**] characteristics.  [**].  Test   [**]  [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]    2. Deliverables.  2.1 Certificate of Analysis (COA) and a final study report  3. Service Fees.  3.1 In addition to fees set forth in Work Order 5997-01 and in prior Change Orders, the  additional fees due to Service Provider for Services included under this Change Order No. 5 shall  be as follows:  

 

CONFIDENTIAL AND PROPRIETARY    [**]  Qty Task Deliverable Direct Fees  Est. Pass Through  Costs Line Total  [**] [**] [**] [**] [**] [**]          [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]   [**]  [**] [**] [**]  Subtotal [**] [**] [**]    The estimated pass through costs are exclusive of the administrative fee.  The administrative fee  of [**]% will be added to the actual cost of the pass-through costs.  3.2 Astrazeneca shall pay Service Provider all fees and costs set forth in this Change Order in  accordance with the following payment schedule: (a) all fees are payable [**]% upfront upon  initiation of the specified activity or task, with the remaining [**]% payable upon completion of  the applicable activity or task; and (b) all pass-through costs plus the administrative fee of [**]%  are payable [**]% upon order placement for the materials or services, with the remaining [**]%  payable upon Service Provider’s receipt of the materials or services.  4. Miscellaneous.  Except as amended herein, all terms and conditions of Work Order  5997-01 remain unchanged and in full force and effect.  IN WITNESS THEREOF, the authorized representatives of the Parties have executed this Change  Order as of the Change Order Effective Date.    ASTRAZENECA PHARMACEUTICALS LP  BY:  /s/ Michelle Vincent   Name: Michelle Vincent  Title: Supplier Relationship Manager  Date: Oct 2, 2020  EMERGENT MANUFACTURING OPERATIONS  BALTIMORE, LLC  BY:  /s/ Jon Lenihan   Name Jon Lenihan  Title: Sr. Dir., Head of Sales & BD  Date: Sep 30, 2020emergentbiosolutionsa41c

Certain identified information has been excluded from the exhibit because it is both (i) not  material and (ii) is the type of information that the registrant treats as private or confidential.  Double asterisks denote omissions.  Exhibit 10.15      CHANGE ORDER NO. 6 TO WORK ORDER #5997-01 – [**] STUDY  This Change Order No. 6 entitled ― [**] STUDY (“Change Order No. 6”) effective as of  October 13, 2020 (“Change Order No. 6 Effective Date”) to Work Order #5997-01 by and between  AstraZeneca Pharmaceuticals LP (“Astrazeneca”) and Emergent Manufacturing Operations  Baltimore, LLC (“Service Provider”) hereby adds to the scope of Services set forth in Work Order  #5997-01 entered into by the Parties pursuant to the Master Services Agreement dated July 24,  2020 (the “Master Services Agreement”).  Capitalized terms used in this Change Order that are  not otherwise defined herein have the meanings given to them in the Master Services Agreement.  In consideration of the mutual promises contained therein and herein and for other good  and valuable consideration the receipt and adequacy of which each of the Parties does hereby  acknowledge, the Parties hereby agree as follows:  1. Purpose and Description of Change.  The purpose of this Change Order No. 6 is to further  add to the Services set forth in Work Order #5997-01.  In addition to the Services set forth in  Work Order #5997-01(including without limitation, within prior Change Orders), Service  Provider will render to Astrazeneca the following Services:  This study will be performed by the Service Provider.  The intent of this study [**].  2. Deliverables.  2.1 Protocol and Report  3. Service Fees.  3.1 In addition to fees set forth in Work Order 5997-01 and in prior Change Orders, the additional  fees due to Service Provider for Services included under this Change Order No. 6 shall be as  follows:  Study  Qty Task Deliverable Direct Fees Est. Pass Through Costs Line Total  [**] [**] [**] [**] [**] [**]  Subtotal [**] [**] [**]  The estimated pass through costs are exclusive of the administrative fee.  The administrative fee  of [**]% will be added to the actual cost of the pass-through costs.  3.2 Astrazeneca shall pay Service Provider all fees and costs set forth in this Change Order in  accordance with the following payment schedule:  (a) all fees are payable [**]% upfront upon  initiation of the specified activity or task, with the remaining [**]% payable upon completion  of the applicable activity or task; and (b) all pass-through costs plus the administrative fee of  [**]% are payable [**]% upon order placement for the materials or services, with the  remaining [**]% payable upon Service Provider’s receipt of the materials or services.  

 

    4. Miscellaneous.  Except as amended herein, all terms and conditions of Work Order 5997-01  remain unchanged and in full force and effect.  IN WITNESS THEREOF, the authorized representatives of the Parties have executed this Change  Order as of the Change Order Effective Date.  ASTRAZENECA PHARMACEUTICALS LP  BY: /s/ Michelle Vincent    Name: Michelle Vincent  Title: Supplier Relationship Manager, BES  Date: November 17, 2020  EMERGENT MANUFACTURING OPERATIONS  BALTIMORE, LLC  BY: /s/ Jon Lenihan     Name: Jon Lenihan  Title: Sr. Dir., Head of Sales & BD  Date: Nov 9, 2020emergentbiosolutionsastr

Certain identified information has been excluded from the exhibit because it is both (i) not  material and (ii) is the type of information that the registrant treats as private or confidential.  Double asterisks denote omissions.  Exhibit 10.16      CHANGE ORDER NO. 10 TO WORK ORDER #5997-01 -     [**] TESTING  This Change Order No. 10 entitled — [**] TESTING (“Change Order No. 10”) effective  as of March 10, 2021 (“Change Order No. 10 Effective Date”) to Work Order #5997-01 by and  between AstraZeneca Pharmaceuticals LP (“AstraZeneca”) and Emergent Manufacturing  Operations Baltimore, LLC (“Service Provider”) hereby adds to the scope of Services set forth  in Work Order #5997-01 entered into by the Parties pursuant to the Master Services Agreement  dated July 24, 2020 (the “Master Services Agreement”).  Capitalized terms used in this Change  Order No. 10 that are not otherwise defined herein have the meanings given to them in the Master  Services Agreement.  In consideration of the mutual promises contained therein and herein and for other good  and valuable consideration the receipt and adequacy of which each of the Parties does hereby  acknowledge, the Parties hereby agree as follows:  1. Purpose and Description of Change.  The purpose of this Change Order No. 10 is to  further add to the Services, and to clarify the specific [**] testing Services, set forth in Work Order  #5997-01.  In addition to the Services set forth in Work Order #5997-01 (including without  limitation, within prior Change Orders), Service Provider will render to AstraZeneca the following  Services:   Work Order #5997-01 had listed [**] testing [**] testing [**] testing.   [**] [**] Testing Deliverable Testing ID  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  

 

  CONFIDENTIAL AND PROPRIETARY     [**] [**] Testing Deliverable Testing ID  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]  [**] [**] [**]    [**] (as per Table 1 below (reference is made to [**]) or as a [**] as per Table 2 below  (reference is made to [**]) after [**] review and any associated [**] reports will be provided.   Table 1: [**] Testing[**]  Method Description* Testing Identification  [**] [**]  [**] [**]  [**] [**]  [**] [**]  [**] [**]  [**] [**]    *Note: For clarity, the method descriptions for [**] testing [**] Service Provider are not as set  forth in the table in paragraph 1.9 in Work Order #5997-01 but are as set forth in Table 1 above.  Table 2: [**] Testing [**]  Method Description* Testing Identification  [**] [**]    

 

  CONFIDENTIAL AND PROPRIETARY    *Note: For clarity, the method descriptions for [**] testing [**] by Service Provider are not as  set forth in the table in paragraph 1.9 in Work Order #5997-01 but are as set forth in Table 2  above.  2. Deliverables.  2.1 For Table 1 testing, [**]  2.2 For Table 2 testing, [**]  3. Service Fees.  3.1 In addition to amounts set forth in Work Order #5997-01 and in prior Change  Orders, the additional amounts due to Service Provider for Services included under  this Change Order No. 10 shall be as follows:  Price per Lot^  [**] Testing Support  Qty Task  Testing  ID Deliverable Direct  Fees  Est. Pass  Through  Costs*  Line  Total  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  ^The above pricing replaces the pricing set forth in Work Order #5997-01 for [**] testing support.   *The estimated pass-through costs are exclusive of the administrative fee.  The administrative fee of [**]% will be  added to the actual cost of the pass-through costs.  Total Price  [**] Testing Support  Qty Task  Testing  ID Deliverable Direct  Fees  Est. Pass  Through  Costs*  Line  Total  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  [**] [**] [**] [**] [**] [**] [**]  Sub Total [**] [**] [**]    *The estimated pass-through costs are exclusive of the administrative fee.  The administrative fee of [**]% will be  added to the actual cost of the pass-through costs.  3.2 AstraZeneca shall pay Service Provider all fees and costs set forth in this Change  Order No. 10 in accordance with the following payment schedule: (a) all fees are  payable [**]% upfront upon initiation of the specified activity or task and (b) all  pass-through costs plus the administrative fee of [**]% are payable [**]% upon  order placement for the materials or services.   

 

  CONFIDENTIAL AND PROPRIETARY    4. Miscellaneous.  Except as amended herein, all terms and conditions of Work Order #5997- 01 remain unchanged and in full force and effect.  IN WITNESS THEREOF, the authorized representatives of the Parties have executed this  Change Order No. 10 as of the Change Order Effective Date.  ASTRAZENECA PHARMACEUTICALS LP  By:  /s/ Michelle Vincent   Name: Michelle Vincent  Title: Supplier Relationship Manager, BES  Date: Apr 1, 2021  EMERGENT MANUFACTURING OPERATIONS  BALTIMORE, LLC  BY:  /s/ Jon Lenihan   Name: Jon Lenihan  Title: Senior Director, Head of Sales & BD  Date: April 2, 2021

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]